skip to Main Content
Roche’s Risdiplam Showed Significant Improvement In Motor Function In People Aged 2-25 With Type 2 Or 3 Spinal Muscular Atrophy

Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy

Roche released part 2 of the SUNFISH data which shows significant improvement both type 2 and type 3 patients. Read on for further details.

The SUNFISH part 2 data is critical as Roche pursues global approval for the use of the treatment. Today is a significant milestone for the introduction of the treatment and shows excellent results which will be used as part of the approval process. The article can be read in full below.

Roche Press Release

Back To Top